[1] Chamcheu JC, Chaves-Rodriquez MI, Adhami VM, et al. Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model [J]. Acta Derm Venereol, 2016, 96(6): 854-856. DOI: 10.2340/00015555-2359.

[2]        Xie X, Zhang L, Li X, et al. Liangxue Jiedu formula improves psoriasis and dyslipidemia comorbidity via PI3K/Akt/mTOR pathway [J]. Front Pharmacol, 2021, 12: 591608. DOI: 10.3389/fphar.2021.591608.

[3]        Yue L, Ailin W, Jinwei Z, et al. PSORI-CM02 ameliorates psoriasis in vivo and in vitro by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway [J]. Phytomedicine, 2019, 64: 153054. DOI: 10.1016/j.phymed.2019.153054.

[4]        Chamcheu JC, Adhami VM, Esnault S, et al. Dual inhibition of PI3K/Akt and mTOR by the dietary antioxidant, delphinidin, ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like disease in mice [J]. Antioxid Redox Signal, 2017, 26(2): 49-69. DOI: 10.1089/ars.2016.6769.

[5]        Wang S, Zhu L, Xu Y, et al. Salvianolic acid B ameliorates psoriatic changes in imiquimod-induced psoriasis on BALB/c mice by inhibiting inflammatory and keratin markers via altering phosphatidylinositol-3-kinase/protein kinase B signaling pathway [J]. Korean J Physiol Pharmacol, 2020, 24(3): 213-221. DOI: 10.4196/kjpp.2020.24.3.213.

[6]        Goulden BD, Pacheco J, Dull A, et al. A high-avidity biosensor reveals plasma membrane PI(3,4)P₂ is predominantly a class I PI3K signaling product [J]. J Cell Biol, 2019, 218(3): 1066-1079. DOI: 10.1083/jcb. 201809026.

[7]        Kang Y, Jang G, Ahn S, et al. Regulation of AKT activity by inhibition of the pleckstrin homology domain-PtdIns(3,4,5)P₃ interaction using flavonoids [J]. J Microbiol Biotechnol, 2018, 28(8): 1401-1411. DOI: 10.4014/jmb.1804.04051.

[8]        Kilic U, Caglayan AB, Beker MC, et al. Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin's neuroprotective activity after focal cerebral ischemia in mice [J]. Redox Biol, 2017, 12: 657-665. DOI: 10.1016/j.redox.2017.04.006.

[9]        Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling [J]. Trends Cell Biol, 2015, 25(9): 545-55. DOI: 10.1016/j.tcb.2015.06.002.

[10]        王昊,冉立伟,惠珂,等.Survivin和PI3K、AKT在寻常型银屑病皮损角质形成细胞中的表达及其相关性[J].南方医科大学学报,2017,37(11):1512-1516. DOI: 10.3969/j.issn. 1673-4254.2017.11.14.

[11]        Zhang M, Zhang X. The role of PI3K/AKT/FOXO signaling in psoriasis [J]. Arch Dermatol Res, 2019, 311(2):83-91. DOI: 10.1007/s00403-018-1879-8.

[12]        Buerger C, Shirsath N, Lang V, et al. Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation [J]. PLoS One, 2017, 12(7): e0180853. DOI: 10.1371/journal.pone.0180853.

[13]        Wang Z, Yu T, Huang P. Post-translational modifications of FOXO family proteins (review) [J]. Mol Med Rep, 2016, 14(6): 4931-4941. DOI: 10.3892/mmr.2016.5867.

[14]        Meduri B, Pujar GV, Durai Ananda Kumar T, et al. Lysophosphatidic acid (LPA) receptor modulators: structural features and recent development [J]. Eur J Med Chem, 2021, 222: 113574. DOI: 10.1016/j.ejmech.2021. 113574.

[15]        Kim D, Kim HJ, Baek JO, et al. Lysophosphatidic acid mediates imiquimod-induced psoriasis-like symptoms by promoting keratinocyte proliferation through LPAR1/ROCK2/PI3K/AKT signaling pathway [J]. Int J Mol Sci, 2021, 22(19): 10777. DOI: 10.3390/ijms221910777.

[16]        Gao J, Guo J, Nong Y, et al. 18β-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice [J]. BMC Pharmacol Toxicol, 2020, 21(1): 41. DOI: 10.1186/s40360-020-00419-0.

[17]        Luengas-Martinez A, Hardman-Smart J, Paus R, et al. Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis [J]. Exp Dermatol, 2020, 29(8): 687-698. DOI: 10.1111/exd.14151.

[18]        Fernández JG, Rodríguez DA, Valenzuela M, et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription [J]. Mol Cancer, 2014, 13: 209. DOI: 10.1186/1476-4598-13-209.

[19]        Lv H, Liu X, Chen W, et al. Yangxue Jiedu Fang ameliorates psoriasis by regulating vascular regression via survivin/PI3K/Akt pathway [J]. J Immunol Res, 2021, 2021: 4678087. DOI: 10.1155/2021/4678087.

[20]        Yu T, Zuber J, Li J. Targeting autophagy in skin diseases [J]. J Mol Med (Berl), 2015, 93(1):31-38. DOI: 10.1007/s00109-014-1225-3.

[21]        Lee HM, Shin DM, Yuk JM, et al. Autophagy negatively regulates keratinocyte inflammatory responses via scaffolding protein p62/SQSTM1 [J]. J Immunol, 2011, 186(2): 1248-1258. DOI: 10.4049/jimmunol.1001954.

[22]        He R, Peng J, Yuan P, et al. Divergent roles of BECN1 in LC3 lipidation and autophagosomal function [J]. Autophagy, 2015, 11(5): 740-747. DOI: 10.1080/15548627.2015. 1034404.

[23]        Varshney P, Saini N. PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis [J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1795-1803. DOI: 10.1016/j.bbadis.2018.02.003.

[24]        Asha K, Singal A, Sharma SB, et al. Dyslipidaemia & oxidative stress in patients of psoriasis: emerging cardiovascular risk factors [J]. Indian J Med Res, 2017, 146(6): 708-713. DOI: 10.4103/ijmr.IJMR_717_16.

[25]        Sajja AP, Joshi AA, Teague HL, et al. Potential immunological links between psoriasis and cardiovascular disease [J]. Front Immunol, 2018, 9: 1234. DOI: 10.3389/fimmu.2018.01234.

[26]        Lu X, Paliogiannis P, Calvisi DF, et al. Role of the mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies [J]. Hepatology, 2021, 73 Suppl 1: 49-61. DOI: 10.1002/hep.31310.

[27]        Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target [J]. Front Immunol, 2018, 9:2786. DOI: 10.3389/fimmu.2018.02786.

[28]       Varshney P, Narasimhan A, Mittal S, et al. Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis [J]. Sci Rep, 2016, 6: 19295. DOI: 10.1038/srep19295.

[29]        Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study [J]. J Am Acad Dermatol, 2007,57(3):529-531. DOI: 10.1016/j.jaad.2007.05.040.

[30]        Asad F, Khan M, Rizvi F. Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in psoriasis [J]. Pak J Med Sci, 2017, 33(6):1507-1511. DOI: 10.12669/pjms.336.14068.

[31]        Malemud CJ. The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? [J]. Future Med Chem, 2015, 7(9): 1137-1147. DOI: 10.4155/fmc.15.55.

[32]        Mercurio L, Morelli M, Scarponi C, et al. PI3Kδ sustains keratinocyte hyperproliferation and epithelial inflammation: implications for a topically druggable target in psoriasis [J]. Cells, 2021, 10(10): 2636. DOI: 10.3390/cells10102636.

[33]        Soares HP, Ming M, Mellon M, et al. Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2 [J]. Mol Cancer Ther, 2015, 14(4):1014-1023. DOI: 10.1158/1535-7163.MCT-14-0669.